Promising Phase I Results for Vernonia Amygdalina Standardized Extract

Our Phase I clinical safety trial for IRL-VA-01, a standardized extract of Vernonia amygdalina (bitter leaf), has completed enrollment with encouraging preliminary results. The trial, conducted at our Lagos clinical facility, enrolled 48 healthy volunteers across four dosing cohorts.

Early data indicates a favorable safety and tolerability profile with no serious adverse events reported. Full results will be submitted for peer review in Q4 2025.